AR054626A1 - Derivados de quinolina como agentes antibacterianos - Google Patents
Derivados de quinolina como agentes antibacterianosInfo
- Publication number
- AR054626A1 AR054626A1 ARP060102787A ARP060102787A AR054626A1 AR 054626 A1 AR054626 A1 AR 054626A1 AR P060102787 A ARP060102787 A AR P060102787A AR P060102787 A ARP060102787 A AR P060102787A AR 054626 A1 AR054626 A1 AR 054626A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- alkyloxy
- hydroxy
- hydrocarbon radical
- halo
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/04—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms
- C07D215/06—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms having only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
- C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Quinoline Compounds (AREA)
Abstract
Reivindicacion 1: Uso de un compuesto para la fabricacion de un medicamento para el tratamiento de una infeccion bacteriana, dicho compuesto es un compuesto de formula (1) o (2), una de sus sales de adicion con ácido o base aceptables desde el punto de vista farmacéutico, una de sus formas estereoquímicamente isoméricas, una de sus formas tautoméricas o uno de sus N-oxidos, en los cuales: R1 es hidrogeno, halo, haloalquilo, ciano, hidroxi, Ar, Het, alquilo, alquiloxi, alquiltio, alquiloxialquilo, alquiltioalquilo, Ar-alquilo o di(Ar)alquilo; p es un numero entero igual a 1, 2, 3 o 4; R2 es hidrogeno, hidroxi, mercapto, alquiloxi, alquiloxialquiloxi, alquiltio, mono o di(alquil)amino o un radical de formula (3), donde Y es CH2, O, S, NH o N-alquilo; R3 es alquilo, Ar, Ar-alquilo, Het o Het-alquilo; q es un numero entero igual a 1, 2 o 3; R4 y R5 son, cada uno en forma independiente, hidrogeno, alquilo o bencilo; o R4 y R5 juntos e incluyendo el N al cual están unidos pueden formar un radical seleccionado del grupo de pirrolidinilo, 2-pirrolidinilo, 3-pirrolinilo, pirrolilo, imidazolidinilo, pirazolidinilo, 2-imidazolinilo, 2-pirazolinilo, imidazolilo, pirazolilo, triazolilo, piperidinilo, piridinilo, piperazinilo, piridazinilo, pirimidinilo, pirazinilo, triazinilo, morfolinilo o tiomorfolinilo, sustituido en forma opcional con alquilo, halo, haloalquilo, hidroxi, alquiloxi, amino, mono- o dialquilamino, alquiltio, alquiloxialquilo, alquiltioalquilo o pirimidinilo; R6 es hidrogeno, halo, haloalquilo, hidroxi, Ar, alquilo, alquiloxi, alquiltio, alquiloxialquilo, alquiltioalquilo, Ar-alquilo o di(Ar)alquilo; o dos radicales R6 vecinos pueden unirse para formar un radical bivalente de formula -CH=CH-CH=CH-; r es un numero entero igual a 1, 2, 3, 4 o 5; R7 es hidrogeno, alquilo, Ar o Het; R8 es hidrogeno o alquilo; R9 es oxo; o R8 y R9 juntos forman el radical -CH=CH-N=; alquilo es un radical de hidrocarburo saturado, recto o ramificado C1-6; o es un radical de hidrocarburo saturado cíclico C3-6; o es un radical de hidrocarburo saturado cíclico C3-6 unido a un radical de hidrocarburo saturado, recto o ramificado, C1-6; donde cada átomo de carbono puede estar sustituido en forma opcional con hidroxi, alquiloxi u oxo; Ar es un homociclo seleccionado del grupo de fenilo, naftilo, acenaftilo, tetrahidronaftilo, cada homociclo sustituido en forma opcional con 1, 2 o 3 sustituyentes, cada sustituyente seleccionado en forma independiente del grupo de hidroxi, halo, ciano, nitro, amino, mono- o dialquilamino, alquilo, haloalquilo, alquiloxi, haloalquiloxi, carboxilo, alquiloxicarbonilo, aminocarbonilo, morfolinilo y mono- o dialquilaminocarbonilo; Het es un heterociclo monocíclico seleccionado del grupo de N-fenoxipiperidinilo, piperidinilo, pirrolilo, pirazolilo, imidazolilo, furanilo, tienilo, oxazolilo, isoxazolilo, tiazolilo, isotiazolilo, piridinilo, pirimidinilo, pirazinilo y piridazinilo; o un heterociclo bicíclico seleccionado del grupo de quinolinilo, quinoxalinilo, indolilo, bencimidazolilo, benzoxazolilo, bencisoxazolilo, benzotiazolilo, bencisotiazolilo, benzofuranilo, benzotienilo, 2,3-dihidrobenzo[1,4]dioxinilo y benzo[1,3]dioxolilo; cada heterociclo monocíclico o bicíclico puede estar sustituido en forma opcional con 1, 2 o 3 sustituyentes, cada sustituyente seleccionado en forma independiente del grupo de halo, hidroxi, alquilo, alquiloxi y Ar-carbonilo; halo es un sustituyente seleccionado del grupo de fluoro, cloro, bromo y yodo; y haloalquilo es un radical de hidrocarburo saturado, recto o ramificado C1-6 o un radical de hidrocarburo cíclico saturado C3-6 o un radical de hidrocarburo cíclico saturado C3-6 unido a un radical de hidrocarburo saturado, recto o ramificado, C1-6; donde uno o más átomos de carbono están sustituidos con uno o más átomos de halo; siempre que la infeccion bacteriana sea distinta de una infeccion por Microbacterias. Reivindicacion 26: Un compuesto en el cual el compuesto se selecciona de las formulas (4) a (17), una de sus sales de adicion con ácido o base aceptables desde el punto de vista farmacéutico, una de sus formas tautoméricas o una de sus formas se N-oxido.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP05105762 | 2005-06-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR054626A1 true AR054626A1 (es) | 2007-07-04 |
Family
ID=34940244
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP060102787A AR054626A1 (es) | 2005-06-28 | 2006-06-28 | Derivados de quinolina como agentes antibacterianos |
Country Status (32)
| Country | Link |
|---|---|
| US (1) | US8841321B2 (es) |
| EP (1) | EP1898914B1 (es) |
| JP (1) | JP5193858B2 (es) |
| KR (1) | KR101329585B1 (es) |
| CN (1) | CN101247811B (es) |
| AP (1) | AP2386A (es) |
| AR (1) | AR054626A1 (es) |
| AU (1) | AU2006263883B2 (es) |
| BR (1) | BRPI0612498A8 (es) |
| CA (1) | CA2612619C (es) |
| CY (1) | CY1113579T1 (es) |
| DK (1) | DK1898914T3 (es) |
| EA (1) | EA014423B1 (es) |
| ES (1) | ES2393203T3 (es) |
| HK (1) | HK1122730A1 (es) |
| HR (1) | HRP20120912T1 (es) |
| IL (1) | IL188393A0 (es) |
| JO (1) | JO2752B1 (es) |
| ME (1) | ME01484B (es) |
| MX (1) | MX2008000081A (es) |
| MY (1) | MY153291A (es) |
| NO (1) | NO342701B1 (es) |
| NZ (1) | NZ564379A (es) |
| PA (1) | PA8683801A1 (es) |
| PL (1) | PL1898914T3 (es) |
| PT (1) | PT1898914E (es) |
| RS (1) | RS52517B (es) |
| SI (1) | SI1898914T1 (es) |
| TW (1) | TWI387457B (es) |
| UA (1) | UA92175C2 (es) |
| WO (1) | WO2007000435A1 (es) |
| ZA (1) | ZA200711165B (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO2970B1 (en) | 2006-12-06 | 2016-03-15 | جانسين فارماسوتيكا ان. في | Quinoline antibacterial derivatives |
| JO2683B1 (en) * | 2006-12-06 | 2013-03-03 | جانسين فارماسوتيكا ان. في | Quinoline antibacterial derivatives |
| EA038350B1 (ru) | 2012-04-27 | 2021-08-12 | Янссен Фармацевтика Нв | Антибактериальные хинолиновые производные |
| ES2576491T3 (es) | 2012-04-27 | 2016-07-07 | Janssen Pharmaceutica, N.V. | Derivados de quinolina antibacterianos |
| EP3237383B1 (en) | 2014-12-23 | 2019-12-04 | Albemarle Corporation | One-step process for the synthesis of alkylated metyrapone analogs |
| CN106928139B (zh) * | 2017-05-08 | 2019-06-25 | 福建省微生物研究所 | 一种贝达喹啉杂质的合成方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19937116A1 (de) * | 1999-08-06 | 2001-02-08 | Bayer Ag | Moxifloxacin Kochsalzformulierung |
| PL222801B1 (pl) * | 2002-07-25 | 2016-09-30 | Janssen Pharmaceutica Nv | Pochodne chinoliny, ich zastosowanie, sposób ich wytwarzania oraz kompozycja farmaceutyczna zawierająca je |
| PL1675852T3 (pl) | 2003-09-22 | 2009-07-31 | Janssen Pharmaceutica Nv | 7-amino-alkilidenylo-heterocykliczne chinolony i naftrydony |
| EP1753427B1 (en) * | 2004-05-28 | 2008-04-02 | Janssen Pharmaceutica N.V. | Use of substituted quinoline derivatives for the treatment of drug resistant mycobacterial diseases |
| EE05394B1 (et) * | 2004-12-24 | 2011-04-15 | Janssen Pharmaceutica N.V. | Kinoliinihendid kasutamiseks latentse tuberkuloosi ravis |
| BRPI0613999B8 (pt) | 2005-06-28 | 2021-05-25 | Janssen Pharmaceutica Nv | uso de um composto derivado de quinolina, o referido composto, sua combinação, composição farmacêutica, uso da referida combinação, e produto |
-
2006
- 2006-06-25 JO JO2006188A patent/JO2752B1/en active
- 2006-06-26 KR KR1020087002107A patent/KR101329585B1/ko active IP Right Grant
- 2006-06-26 ES ES06763889T patent/ES2393203T3/es active Active
- 2006-06-26 EP EP06763889A patent/EP1898914B1/en active Active
- 2006-06-26 JP JP2008518810A patent/JP5193858B2/ja not_active Expired - Fee Related
- 2006-06-26 DK DK06763889.0T patent/DK1898914T3/da active
- 2006-06-26 BR BRPI0612498A patent/BRPI0612498A8/pt not_active Application Discontinuation
- 2006-06-26 AU AU2006263883A patent/AU2006263883B2/en not_active Ceased
- 2006-06-26 PT PT06763889T patent/PT1898914E/pt unknown
- 2006-06-26 ME MEP-2012-127A patent/ME01484B/me unknown
- 2006-06-26 MX MX2008000081A patent/MX2008000081A/es active IP Right Grant
- 2006-06-26 EA EA200800154A patent/EA014423B1/ru unknown
- 2006-06-26 US US11/993,145 patent/US8841321B2/en not_active Expired - Fee Related
- 2006-06-26 RS RS20120480A patent/RS52517B/en unknown
- 2006-06-26 NZ NZ564379A patent/NZ564379A/en not_active IP Right Cessation
- 2006-06-26 CA CA2612619A patent/CA2612619C/en not_active Expired - Fee Related
- 2006-06-26 AP AP2008004303A patent/AP2386A/xx active
- 2006-06-26 CN CN2006800310552A patent/CN101247811B/zh not_active Expired - Fee Related
- 2006-06-26 PL PL06763889T patent/PL1898914T3/pl unknown
- 2006-06-26 SI SI200631468T patent/SI1898914T1/sl unknown
- 2006-06-26 WO PCT/EP2006/063553 patent/WO2007000435A1/en active Application Filing
- 2006-06-26 UA UAA200714927A patent/UA92175C2/ru unknown
- 2006-06-27 MY MYPI20063044A patent/MY153291A/en unknown
- 2006-06-27 TW TW095123127A patent/TWI387457B/zh not_active IP Right Cessation
- 2006-06-28 PA PA20068683801A patent/PA8683801A1/es unknown
- 2006-06-28 AR ARP060102787A patent/AR054626A1/es unknown
-
2007
- 2007-12-20 ZA ZA2007/11165A patent/ZA200711165B/en unknown
- 2007-12-25 IL IL188393A patent/IL188393A0/en active IP Right Grant
-
2008
- 2008-01-28 NO NO20080501A patent/NO342701B1/no not_active IP Right Cessation
- 2008-12-24 HK HK08113967.4A patent/HK1122730A1/xx not_active IP Right Cessation
-
2012
- 2012-11-13 HR HRP20120912TT patent/HRP20120912T1/hr unknown
- 2012-11-14 CY CY20121101090T patent/CY1113579T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR051790A1 (es) | Tratamiento de tuberculosis latente | |
| AR049127A1 (es) | Uso de derivados quinolina sustituidos para el tratamiento de enfermedades micobacterianas resistentes a los farmacos | |
| AR040673A1 (es) | Inhibidores micobacterianos, composicion farmaceutica y proceso de preparacion del compuesto | |
| CY1120248T1 (el) | Ενωσεις ιμιδαζο[4,5-c]κινολιν-2-ονης και η χρηση τους στη θεραπευτικη αντιμετωπιση του καρκινου | |
| AR064151A1 (es) | Derivados de quinolina antibacterianos, composiciones farmaceuticas que los contienen y metodo de preparacion. | |
| AR054889A1 (es) | Derivados de quinolina como agentes bacterianos | |
| AR097024A1 (es) | Derivados sustituidos de quinazolin-4-ona | |
| CY1124680T1 (el) | Παραγωγα 8-[6-[3-(αμινο)προποξυ]-3-πυριδυλο]-1-ισοπροπυλο-ιμιδαζο[4,5-c]κινολιν-2-ονης ως εκλεκτiκοι ρυθμιστες κινασης μεταλλαγμενης αταξιας τελαγγειεκτασιας (atm) για τη θεραπευτικη αγωγη του καρκινου | |
| BRPI0612888B8 (pt) | anilino-piridinotriazinas cíclicas como inibidoras de gsk-3, seus usos e composição farmacêutica, intermediário, seu uso e composição farmacêutica | |
| TR201906123T4 (tr) | P13 kinazı ve mtor inhibitörleri olarak triazin bileşikleri. | |
| DOP2018000187A (es) | Derivados de pirazolo[1,5-a]pirazin-4-ilo | |
| IS8503A (is) | Azatvíhringja heteróhringir sem kannabínóníð-viðtakastillar | |
| AR054626A1 (es) | Derivados de quinolina como agentes antibacterianos | |
| AR081058A1 (es) | Derivados de arilmetoxi isoindolina, composiciones que los comprenden y su uso en el tratamiento del cancer. | |
| PA8520301A1 (es) | Derivados biciclicos sustituidos para el tratamiento del crecimiento celular anormal | |
| EA201000947A1 (ru) | Производные тиазола, применимые в качестве ингибиторов киназы pi3 | |
| PE20060459A1 (es) | DERIVADOS DE AMINO-5,5-DIFENILIMIDAZOLONA COMO INHIBIDORES DE LA ß-SECRETASA | |
| AR089910A1 (es) | Composiciones veterinarias orales parasiticidas que comprenden agentes activos de accion sistemica, metodos y usos de las mismas | |
| ECSP105253A (es) | Derivados de 5-feniltiazol y uso como inhibidores de pi3 cinasa | |
| TW200626154A (en) | Heterocyclic derivatives and their use as therapeutic agents | |
| UY30641A1 (es) | Derivados de 2-[1h-pirazol-5-il] y de 2-[2h-pirazol-3-il]tieno[3,2-c]piridinas sustituidas, sus sales farmaceuticamente aceptables y aplicaciones | |
| AR054804A1 (es) | Derivados de quinolina, composicion farmaceutica que los comprende y su uso en combinacion con otros agentes antibacterianos para el tratamiento de infecciones bacterianas | |
| AR056321A1 (es) | COMBINACIONES TERAPÉUTICAS PARA EL TRATAMIENTO O LA PREVENCIoN DE TRASTORNOS PSICoTICOS | |
| AR105544A1 (es) | Compuestos de n-carboxamida cíclica útiles como herbicidas | |
| MX2009012613A (es) | Tiazoles substituidos por heteroarilo y su uso como agentes antivirales. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |